Retrospective Analysis of Metastatic Colorectal Cancer

Clinical information of patients, including age, body mass index, TNM stage, tumor location, pathological differentiation, lymph node metastasis, nerve invasion, vascular invasion, RAS status, and BRAF status, was retrospectively collected from medical records. Follow-up was carried out via telephone or by returning to the hospital for examination. The last follow-up was on July 12, 2021. Any metastasis with an interval of more than 3 months between the diagnosis of primary tumor (PT) and ovarian metastasis was defined as metachronous; otherwise, it was considered synchronous metastasis. The time from patients receiving first-line antitumor treatment to death from any cause was overall survival (OS), whereas the time of tumor progression, death from any cause, or time to receiving second-line treatment was progression-free survival (PFS). The Ethics Committee of Guangxi Medical University Cancer Hospital approved our study (LW2021078).